Idiopathische Lungenfibrose – Epidemiologie, Ursachen und klinischer Verlauf

Araki T, Putman RK, Hatabu H et al (2016) Development and progression of interstitial lung abnormalities in the Framingham heart study. Am J Respir Crit Care Med 194:1514–1522

Depianto DJ, Chandriani S, Abbas AR et al (2015) Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis. Thorax 70:48–56

Diaz De Leon A, Cronkhite JT, Yilmaz C et al (2011) Subclinical lung disease, macrocytosis, and premature graying in kindreds with telomerase (TERT) mutations. Chest 140:753–763

Garcia-Sancho C, Buendia-Roldan I, Fernandez-Plata MR et al (2011) Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis. Respir Med 105:1902–1907

Hackett NR, Butler MW, Shaykhiev R et al (2012) RNA-Seq quantification of the human small airway epithelium transcriptome. BMC Genomics 13:82

Hutchinson J, Fogarty A, Hubbard R et al (2015) Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J 46:795–806

Idiopathic Pulmonary Fibrosis Clinical Research Network (2012) Prednisone, azathioprine, and N‑acetylcysteine for pulmonary fibrosis. N Engl J Med 366:1968–1977

Koelink PJ, Overbeek SA, Braber S et al (2012) Targeting chemokine receptors in chronic inflammatory diseases: an extensive review. Pharmacol Ther 133:1–18

Kropski JA, Pritchett JM, Zoz DF et al (2015) Extensive phenotyping of individuals at risk for familial interstitial pneumonia reveals clues to the pathogenesis of interstitial lung disease. Am J Respir Crit Care Med 191:417–426

Lederer DJ, Martinez FJ (2018) Idiopathic pulmonary fibrosis. N Engl J Med 378:1811–1823

Lee SH, Park JS, Kim SY et al (2018) Comparison of CPI and GAP models in patients with idiopathic pulmonary fibrosis: a nationwide cohort study. Sci Rep 8:4784

Ley B, Newton CA, Arnould I et al (2017) The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis: an observational cohort-control study. Lancet Respir Med 5:639–647

Mercer PF, Chambers RC (2016) Innate immune signaling and stem cell renewal in idiopathic pulmonary fibrosis. Nat Med 22:1210–1212

Moore C, Blumhagen RZ, Yang IV et al (2019) Resequencing study confirms that host defense and cell senescence gene variants contribute to the risk of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 200:199–208

Newton CA, Batra K, Torrealba J et al (2016) Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive. Eur Respir J 48:1710–1720

Noth I, Zhang Y, Ma SF et al (2013) Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med 1:309–317

Nuovo GJ, Hagood JS, Magro CM et al (2012) The distribution of immunomodulatory cells in the lungs of patients with idiopathic pulmonary fibrosis. Mod Pathol 25:416–433

Oldham JM, Ma SF, Martinez FJ et al (2015) TOLLIP, MUC5B, and the response to N‑acetylcysteine among individuals with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 192:1475–1482

Peljto AL, Selman M, Kim DS et al (2015) The MUC5B promoter polymorphism is associated with idiopathic pulmonary fibrosis in a Mexican cohort but is rare among Asian ancestries. Chest 147:460–464

Putman RK, Hatabu H, Araki T et al (2016) Association between interstitial lung abnormalities and all-cause mortality. JAMA 315:672–681

Raghu G, Remy-Jardin M, Myers JL et al (2018) Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 198:e44–e68

Richeldi L, Collard HR, Jones MG (2017) Idiopathic pulmonary fibrosis. Lancet 389:1941–1952

Roy MG, Livraghi-Butrico A, Fletcher AA et al (2014) Muc5b is required for airway defence. Nature 505:412–416

Seibold MA, Wise AL, Speer MC et al (2011) A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 364:1503–1512

Steele MP, Speer MC, Loyd JE et al (2005) Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med 172:1146–1152

Stock CJ, Sato H, Fonseca C et al (2013) Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax 68:436–441

Swigris JJ, Olson AL, Huie TJ et al (2012) Ethnic and racial differences in the presence of idiopathic pulmonary fibrosis at death. Respir Med 106:588–593

Townsley DM, Dumitriu B, Liu D et al (2016) Danazol treatment for telomere diseases. N Engl J Med 374:1922–1931

Tsakiri KD, Cronkhite JT, Kuan PJ et al (2007) Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci U S A 104:7552–7557